Global /Sweden /Healthcare /Drug Manufacturers - General /FLERIE

Flerie AB (publ)

FLERIE

• STO: FLERIE • Delayed

26.50SEK -3.3%

2.83 USD

As of 5 June 2026, Flerie AB (publ) has a market cap of $242.41M USD, ranking #19889 globally and #249 in Sweden. It ranks #1791 in the Healthcare sector, and #651 in the Drug Manufacturers - General industry.

Global Rank

19889

Country Rank

249

Sector Rank

1791

Industry Rank

651

Key Stats

Market Cap

$242.41MUSD

2.28B SEK

Enterprise Value

$181.06MUSD

1.7B SEK

Revenue (TTM)

$191.35KUSD

1.8M SEK

EBITDA (TTM)

-$3.64MUSD

-34.1M SEK

Net Income (TTM)

-$60.31MUSD

-567.3M SEK

PS Ratio

1266.8

PB Ratio

0.6

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Ted Fjallman open_in_new

Employees

Founded

2011

Website

flerie.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.3%	-4.3%	-27%	-27%	-35%	-29%	-35%	-52%	-52%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	FLERIE Flerie AB ISIN: SE0022447348 Shares Out.: Shares Outstanding: 91.021M¹ Shares Float: 8.551M² TV: TradingView: OMXSTO: FLERIE SA: Stock Analysis: STO: FLERIE YF: Yahoo Finance: FLERIE.ST GF: Google Finance: STO: FLERIE BA: Barron's: FLERIE MS: Morningstar: XSTO: FLERIE	26.50 SEK	TV: TradingView: OMXSTO: FLERIE SA: Stock Analysis: STO: FLERIE YF: Yahoo Finance: FLERIE.ST GF: Google Finance: STO: FLERIE BA: Barron's: FLERIE MS: Morningstar: XSTO: FLERIE

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Flerie AB (publ)

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.

Similar Companies

Industry: Drug Manufacturers - General (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Swedish Orphan Biovitrum AB (publ) STO: SOBI	$14.82B 139.44B SEK 6K%	152.8	Sweden
Camurus AB (publ) STO: CAMX	$3.33B 31.37B SEK 1K%	42.8	Sweden
BioArctic AB (publ) STO: BIOA-B	$2.92B 27.5B SEK 1K%	26.9	Sweden
Swedencare AB (publ) STO: SECARE	$450.3M 4.24B SEK 86%	85.9	Sweden
Vicore Pharma Holding AB (publ) STO: VICO	$299.88M 2.82B SEK 24%	-	Sweden
Hansa Biopharma AB (publ) STO: HNSA	$292.96M 2.76B SEK 21%	-	Sweden

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 314K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 226K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 149K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 133K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 119K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 114K%	20.5	Switzerland

chevron_leftBack